All In Biotech

Investigational drug · Phase 3

AK3280

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis (IPF).

Phase 3

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "AK3280"

First trial start

2026

Aug 31, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AK3280", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Idiopathic Pulmonary Fibrosis (IPF)

Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "AK3280" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Idiopathic Pulmonary Fibrosis (IPF)

  • HSK44459Phase 39 trials

    Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis

  • HEC585Phase 33 trials

    Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

  • DeupirfenidonePhase 32 trials

    PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis

  • INS018_055Phase 32 trials

    InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis

  • TDI01Phase 32 trials

    Beijing Tide Pharmaceutical Co., Ltd · GVHD, Chronic, Idiopathic Pulmonary Fibrosis (IPF)

  • HB0056Phase 22 trials

    Shanghai Huaota Biopharmaceutical Co., Ltd. · Asthma, Idiopathic Pulmonary Fibrosis (IPF)

  • AGMB-447Phase 21 trial

    Agomab Spain S.L.U. · Idiopathic Pulmonary Fibrosis (IPF)

  • AP02Phase 21 trial

    Avalyn Pharma Inc. · Idiopathic Pulmonary Fibrosis (IPF)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.